Clinical Study to Evaluate Tolerability and Safety of ARK-E021 Foam and to Monitor Clinical Effect in Acne Vulgaris Patients

NCT01494285 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

157

Enrollment

OTHER

Sponsor class

Conditions

Acne Vulgaris

Interventions

DRUG: ARK-E021 5%
DRUG: ARK-E021 10%
DRUG: Placebo

Sponsor

M. Arkin 1999 Ltd.

Collaborators

[object Object]